SEP 1, 2026 · JOURNAL ARTICLE
A Transdermal CRISPR/Cas9 Strategy Using Biodegradable Microneedles to Target YB-1 in Melanoma
Materials Today Bio
Early-stage preclinical work demonstrating proof-of-concept in cell and animal models; no human data, surrogate endpoints only, and no direct clinical comparator.
Reported
In vitro dual-drug delivery rate74.4%
Gene editing efficiency65.32%
Tumor cell viability after CNPs@D…3.51%